Drug repurposing—an emerging strategy in cancer therapeutics

Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Naunyn-Schmiedeberg's archives of pharmacology 2022-10, Vol.395 (10), p.1139-1158
Hauptverfasser: Turabi, Khadija Shahab, Deshmukh, Ankita, Paul, Sayan, Swami, Dayanand, Siddiqui, Shafina, Kumar, Urwashi, Naikar, Shreelekha, Devarajan, Shine, Basu, Soumya, Paul, Manash K., Aich, Jyotirmoi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1158
container_issue 10
container_start_page 1139
container_title Naunyn-Schmiedeberg's archives of pharmacology
container_volume 395
creator Turabi, Khadija Shahab
Deshmukh, Ankita
Paul, Sayan
Swami, Dayanand
Siddiqui, Shafina
Kumar, Urwashi
Naikar, Shreelekha
Devarajan, Shine
Basu, Soumya
Paul, Manash K.
Aich, Jyotirmoi
description Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.
doi_str_mv 10.1007/s00210-022-02263-x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2675981868</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2713092967</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-da3eed56eb84ce51afd815a579d67749db3a5cb7d387d03e1756c773f846dd203</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotlZfwIUMuHEzmktz2whSr1Bwo-uQJqfjlHZmTGag3fkQPqFPYmqrggsX4RDOd_5z-BA6JvicYCwvIsaU4BxTun6C5csd1CdDRnOiCd1F_dRXOaFa9dBBjDOMsSCc76Me40JzTUgfXV6HrsgCNF1o6lhWxcfbu60yWEAo0i-LbbAtFKusrDJnKwcha18g2Aa6tnTxEO1N7TzC0bYO0PPtzdPoPh8_3j2Mrsa5Y5i3ubcMwHMBEzV0wImdekW45VJ7IeVQ-wmz3E2kZ0p6zIBILpyUbKqGwnuK2QCdbXKbUL92EFuzKKOD-dxWUHfRUCG5VkQJldDTP-is7kKVrjNUEoY11UImim4oF-oYA0xNE8qFDStDsFnbNRu7Jpk1X3bNMg2dbKO7yQL8z8i3zgSwDRBTqyog_O7-J_YTxk2GGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2713092967</pqid></control><display><type>article</type><title>Drug repurposing—an emerging strategy in cancer therapeutics</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Turabi, Khadija Shahab ; Deshmukh, Ankita ; Paul, Sayan ; Swami, Dayanand ; Siddiqui, Shafina ; Kumar, Urwashi ; Naikar, Shreelekha ; Devarajan, Shine ; Basu, Soumya ; Paul, Manash K. ; Aich, Jyotirmoi</creator><creatorcontrib>Turabi, Khadija Shahab ; Deshmukh, Ankita ; Paul, Sayan ; Swami, Dayanand ; Siddiqui, Shafina ; Kumar, Urwashi ; Naikar, Shreelekha ; Devarajan, Shine ; Basu, Soumya ; Paul, Manash K. ; Aich, Jyotirmoi</creatorcontrib><description>Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.</description><identifier>ISSN: 0028-1298</identifier><identifier>EISSN: 1432-1912</identifier><identifier>DOI: 10.1007/s00210-022-02263-x</identifier><identifier>PMID: 35695911</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antidiabetics ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Artificial Intelligence ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer therapies ; Chemotherapy ; Clinical trials ; Computer applications ; Drug development ; Drug discovery ; Drug Repositioning - methods ; Drugs ; Humans ; Neoplasms - drug therapy ; Neurosciences ; Pharmacology/Toxicology ; Proteomics ; Radiation therapy ; Review ; Side effects</subject><ispartof>Naunyn-Schmiedeberg's archives of pharmacology, 2022-10, Vol.395 (10), p.1139-1158</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-da3eed56eb84ce51afd815a579d67749db3a5cb7d387d03e1756c773f846dd203</citedby><cites>FETCH-LOGICAL-c305t-da3eed56eb84ce51afd815a579d67749db3a5cb7d387d03e1756c773f846dd203</cites><orcidid>0000-0001-6842-5724 ; 0000-0002-6180-3785 ; 0000-0002-0990-7392 ; 0000-0001-6620-950X ; 0000-0002-0889-6767 ; 0000-0002-9404-0024 ; 0000-0002-0372-6435 ; 0000-0002-1726-0154 ; 0000-0002-8840-4768 ; 0000-0003-1252-6942 ; 0000-0003-2133-8011</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00210-022-02263-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00210-022-02263-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35695911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turabi, Khadija Shahab</creatorcontrib><creatorcontrib>Deshmukh, Ankita</creatorcontrib><creatorcontrib>Paul, Sayan</creatorcontrib><creatorcontrib>Swami, Dayanand</creatorcontrib><creatorcontrib>Siddiqui, Shafina</creatorcontrib><creatorcontrib>Kumar, Urwashi</creatorcontrib><creatorcontrib>Naikar, Shreelekha</creatorcontrib><creatorcontrib>Devarajan, Shine</creatorcontrib><creatorcontrib>Basu, Soumya</creatorcontrib><creatorcontrib>Paul, Manash K.</creatorcontrib><creatorcontrib>Aich, Jyotirmoi</creatorcontrib><title>Drug repurposing—an emerging strategy in cancer therapeutics</title><title>Naunyn-Schmiedeberg's archives of pharmacology</title><addtitle>Naunyn-Schmiedeberg's Arch Pharmacol</addtitle><addtitle>Naunyn Schmiedebergs Arch Pharmacol</addtitle><description>Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.</description><subject>Antidiabetics</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Artificial Intelligence</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Computer applications</subject><subject>Drug development</subject><subject>Drug discovery</subject><subject>Drug Repositioning - methods</subject><subject>Drugs</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neurosciences</subject><subject>Pharmacology/Toxicology</subject><subject>Proteomics</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>Side effects</subject><issn>0028-1298</issn><issn>1432-1912</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMtKAzEUhoMotlZfwIUMuHEzmktz2whSr1Bwo-uQJqfjlHZmTGag3fkQPqFPYmqrggsX4RDOd_5z-BA6JvicYCwvIsaU4BxTun6C5csd1CdDRnOiCd1F_dRXOaFa9dBBjDOMsSCc76Me40JzTUgfXV6HrsgCNF1o6lhWxcfbu60yWEAo0i-LbbAtFKusrDJnKwcha18g2Aa6tnTxEO1N7TzC0bYO0PPtzdPoPh8_3j2Mrsa5Y5i3ubcMwHMBEzV0wImdekW45VJ7IeVQ-wmz3E2kZ0p6zIBILpyUbKqGwnuK2QCdbXKbUL92EFuzKKOD-dxWUHfRUCG5VkQJldDTP-is7kKVrjNUEoY11UImim4oF-oYA0xNE8qFDStDsFnbNRu7Jpk1X3bNMg2dbKO7yQL8z8i3zgSwDRBTqyog_O7-J_YTxk2GGw</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Turabi, Khadija Shahab</creator><creator>Deshmukh, Ankita</creator><creator>Paul, Sayan</creator><creator>Swami, Dayanand</creator><creator>Siddiqui, Shafina</creator><creator>Kumar, Urwashi</creator><creator>Naikar, Shreelekha</creator><creator>Devarajan, Shine</creator><creator>Basu, Soumya</creator><creator>Paul, Manash K.</creator><creator>Aich, Jyotirmoi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6842-5724</orcidid><orcidid>https://orcid.org/0000-0002-6180-3785</orcidid><orcidid>https://orcid.org/0000-0002-0990-7392</orcidid><orcidid>https://orcid.org/0000-0001-6620-950X</orcidid><orcidid>https://orcid.org/0000-0002-0889-6767</orcidid><orcidid>https://orcid.org/0000-0002-9404-0024</orcidid><orcidid>https://orcid.org/0000-0002-0372-6435</orcidid><orcidid>https://orcid.org/0000-0002-1726-0154</orcidid><orcidid>https://orcid.org/0000-0002-8840-4768</orcidid><orcidid>https://orcid.org/0000-0003-1252-6942</orcidid><orcidid>https://orcid.org/0000-0003-2133-8011</orcidid></search><sort><creationdate>20221001</creationdate><title>Drug repurposing—an emerging strategy in cancer therapeutics</title><author>Turabi, Khadija Shahab ; Deshmukh, Ankita ; Paul, Sayan ; Swami, Dayanand ; Siddiqui, Shafina ; Kumar, Urwashi ; Naikar, Shreelekha ; Devarajan, Shine ; Basu, Soumya ; Paul, Manash K. ; Aich, Jyotirmoi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-da3eed56eb84ce51afd815a579d67749db3a5cb7d387d03e1756c773f846dd203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antidiabetics</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Artificial Intelligence</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Computer applications</topic><topic>Drug development</topic><topic>Drug discovery</topic><topic>Drug Repositioning - methods</topic><topic>Drugs</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neurosciences</topic><topic>Pharmacology/Toxicology</topic><topic>Proteomics</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turabi, Khadija Shahab</creatorcontrib><creatorcontrib>Deshmukh, Ankita</creatorcontrib><creatorcontrib>Paul, Sayan</creatorcontrib><creatorcontrib>Swami, Dayanand</creatorcontrib><creatorcontrib>Siddiqui, Shafina</creatorcontrib><creatorcontrib>Kumar, Urwashi</creatorcontrib><creatorcontrib>Naikar, Shreelekha</creatorcontrib><creatorcontrib>Devarajan, Shine</creatorcontrib><creatorcontrib>Basu, Soumya</creatorcontrib><creatorcontrib>Paul, Manash K.</creatorcontrib><creatorcontrib>Aich, Jyotirmoi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Naunyn-Schmiedeberg's archives of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turabi, Khadija Shahab</au><au>Deshmukh, Ankita</au><au>Paul, Sayan</au><au>Swami, Dayanand</au><au>Siddiqui, Shafina</au><au>Kumar, Urwashi</au><au>Naikar, Shreelekha</au><au>Devarajan, Shine</au><au>Basu, Soumya</au><au>Paul, Manash K.</au><au>Aich, Jyotirmoi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug repurposing—an emerging strategy in cancer therapeutics</atitle><jtitle>Naunyn-Schmiedeberg's archives of pharmacology</jtitle><stitle>Naunyn-Schmiedeberg's Arch Pharmacol</stitle><addtitle>Naunyn Schmiedebergs Arch Pharmacol</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>395</volume><issue>10</issue><spage>1139</spage><epage>1158</epage><pages>1139-1158</pages><issn>0028-1298</issn><eissn>1432-1912</eissn><abstract>Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35695911</pmid><doi>10.1007/s00210-022-02263-x</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0001-6842-5724</orcidid><orcidid>https://orcid.org/0000-0002-6180-3785</orcidid><orcidid>https://orcid.org/0000-0002-0990-7392</orcidid><orcidid>https://orcid.org/0000-0001-6620-950X</orcidid><orcidid>https://orcid.org/0000-0002-0889-6767</orcidid><orcidid>https://orcid.org/0000-0002-9404-0024</orcidid><orcidid>https://orcid.org/0000-0002-0372-6435</orcidid><orcidid>https://orcid.org/0000-0002-1726-0154</orcidid><orcidid>https://orcid.org/0000-0002-8840-4768</orcidid><orcidid>https://orcid.org/0000-0003-1252-6942</orcidid><orcidid>https://orcid.org/0000-0003-2133-8011</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0028-1298
ispartof Naunyn-Schmiedeberg's archives of pharmacology, 2022-10, Vol.395 (10), p.1139-1158
issn 0028-1298
1432-1912
language eng
recordid cdi_proquest_miscellaneous_2675981868
source MEDLINE; SpringerNature Journals
subjects Antidiabetics
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Artificial Intelligence
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer therapies
Chemotherapy
Clinical trials
Computer applications
Drug development
Drug discovery
Drug Repositioning - methods
Drugs
Humans
Neoplasms - drug therapy
Neurosciences
Pharmacology/Toxicology
Proteomics
Radiation therapy
Review
Side effects
title Drug repurposing—an emerging strategy in cancer therapeutics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T15%3A44%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20repurposing%E2%80%94an%20emerging%20strategy%20in%20cancer%20therapeutics&rft.jtitle=Naunyn-Schmiedeberg's%20archives%20of%20pharmacology&rft.au=Turabi,%20Khadija%20Shahab&rft.date=2022-10-01&rft.volume=395&rft.issue=10&rft.spage=1139&rft.epage=1158&rft.pages=1139-1158&rft.issn=0028-1298&rft.eissn=1432-1912&rft_id=info:doi/10.1007/s00210-022-02263-x&rft_dat=%3Cproquest_cross%3E2713092967%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2713092967&rft_id=info:pmid/35695911&rfr_iscdi=true